The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta89
1 Guidance
|
This guidance replaces 'Autologous cartilage transplantation for full thickness cartilage defects in knee joints' (NICE Technology Appraisal Guidance 16) issued in December 2000. For details, see 'About this guidance'. |
1.1 Autologous chondrocyte implantation (ACI) is not recommended for the treatment of articular cartilage defects of the knee joint except in the context of ongoing or new clinical studies that are designed to generate robust and relevant outcome data, including the measurement of health-related quality of life and long-term follow-up. Patients should be fully informed of the uncertainties about the long-term effectiveness and the potential adverse effects of this procedure.